Roivant Sciences Ltd. (NASDAQ:ROIV) Receives $17.69 Consensus PT from Analysts

Shares of Roivant Sciences Ltd. (NASDAQ:ROIV) have been assigned a consensus rating of “Moderate Buy” from the eight ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation and seven have given a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $17.93.

Several brokerages have issued reports on ROIV. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a research note on Wednesday. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Roivant Sciences in a research report on Thursday, September 19th. Finally, Bank of America upped their target price on Roivant Sciences from $12.00 to $12.50 and gave the stock a “neutral” rating in a report on Wednesday, September 11th.

Insider Buying and Selling

In related news, CAO Rakhi Kumar sold 250,000 shares of Roivant Sciences stock in a transaction dated Monday, September 23rd. The shares were sold at an average price of $11.89, for a total transaction of $2,972,500.00. Following the completion of the sale, the chief accounting officer now owns 209,322 shares of the company’s stock, valued at approximately $2,488,838.58. The trade was a 54.43 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, COO Eric Venker sold 100,000 shares of the stock in a transaction dated Monday, October 21st. The shares were sold at an average price of $11.65, for a total transaction of $1,165,000.00. Following the completion of the transaction, the chief operating officer now directly owns 617,470 shares in the company, valued at approximately $7,193,525.50. This represents a 13.94 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 3,577,309 shares of company stock worth $42,151,184. Company insiders own 7.90% of the company’s stock.

Institutional Investors Weigh In On Roivant Sciences

Institutional investors have recently made changes to their positions in the company. American International Group Inc. lifted its holdings in Roivant Sciences by 7,589.5% during the 1st quarter. American International Group Inc. now owns 450,065 shares of the company’s stock worth $4,744,000 after purchasing an additional 444,212 shares during the last quarter. Magnetar Financial LLC bought a new stake in shares of Roivant Sciences in the first quarter valued at about $1,576,000. Ameritas Investment Partners Inc. acquired a new position in shares of Roivant Sciences in the first quarter valued at about $784,000. Clearbridge Investments LLC acquired a new position in shares of Roivant Sciences in the first quarter valued at about $12,962,000. Finally, Cetera Advisors LLC bought a new position in Roivant Sciences during the first quarter worth about $758,000. Institutional investors own 64.76% of the company’s stock.

Roivant Sciences Stock Down 3.8 %

Shares of ROIV stock opened at $11.20 on Thursday. Roivant Sciences has a 12 month low of $8.56 and a 12 month high of $13.06. The company’s fifty day simple moving average is $11.75 and its 200-day simple moving average is $11.32. The firm has a market cap of $8.28 billion, a PE ratio of 1.98 and a beta of 1.24.

About Roivant Sciences

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.